DE69939155D1 - Disulfiram enthaltende arzneimittel - Google Patents

Disulfiram enthaltende arzneimittel

Info

Publication number
DE69939155D1
DE69939155D1 DE69939155T DE69939155T DE69939155D1 DE 69939155 D1 DE69939155 D1 DE 69939155D1 DE 69939155 T DE69939155 T DE 69939155T DE 69939155 T DE69939155 T DE 69939155T DE 69939155 D1 DE69939155 D1 DE 69939155D1
Authority
DE
Germany
Prior art keywords
disciple
products containing
medicinal products
disulfiram
containing disulfiram
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69939155T
Other languages
German (de)
English (en)
Inventor
Moshe Marikovsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Application granted granted Critical
Publication of DE69939155D1 publication Critical patent/DE69939155D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
DE69939155T 1998-01-11 1999-01-11 Disulfiram enthaltende arzneimittel Expired - Lifetime DE69939155D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL12289298A IL122892A0 (en) 1998-01-11 1998-01-11 Pharmaceutical compositions comprising a thiocarbamate
PCT/IL1999/000017 WO1999034784A2 (en) 1998-01-11 1999-01-11 Pharmaceutical compositions comprising disulfiram for inhibiting angiogenesis

Publications (1)

Publication Number Publication Date
DE69939155D1 true DE69939155D1 (de) 2008-09-04

Family

ID=11071076

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69939155T Expired - Lifetime DE69939155D1 (de) 1998-01-11 1999-01-11 Disulfiram enthaltende arzneimittel

Country Status (9)

Country Link
US (1) US6288110B1 (enExample)
EP (1) EP1047416B1 (enExample)
JP (1) JP2002500180A (enExample)
AT (1) ATE401879T1 (enExample)
AU (1) AU1888599A (enExample)
DE (1) DE69939155D1 (enExample)
DK (1) DK1047416T3 (enExample)
IL (1) IL122892A0 (enExample)
WO (1) WO1999034784A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6589987B2 (en) 1998-09-08 2003-07-08 Charlotte-Mecklenburg Hospital Authority Method of treating cancer using tetraethyl thiuram disulfide
US6706759B1 (en) 1998-09-08 2004-03-16 Charlotte-Mecklenburg Hospital Authority Method of treating cancer using dithiocarbamate derivatives
US6548540B2 (en) * 1998-09-08 2003-04-15 Charlotte-Mecklenburg Hospital Authority Method of treating cancer using dithiocarbamate derivatives
US7816403B2 (en) * 1998-09-08 2010-10-19 University Of Utah Research Foundation Method of inhibiting ATF/CREB and cancer cell growth and pharmaceutical compositions for same
AU2002226650A1 (en) * 2001-01-18 2002-07-30 Arnold Hoffman Redox therapy for tumors
US20040157837A1 (en) * 2002-11-07 2004-08-12 Serbedzija George N. Combinations for the treatment of fungal infections
WO2007065167A1 (en) * 2005-12-02 2007-06-07 The Johns Hopkins University Use of high-dose oxazaphosphorine drugs for treating immune disorders
WO2008034074A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclosphosphamide in combination with anti-idiotypic vaccines
WO2008034071A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Method of identifying patients suitable for high-dose cyclophosphamide treatment
WO2008034076A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclophosphamide in combination with immune therapeutics
WO2008068746A2 (en) * 2006-12-04 2008-06-12 Yeda Research And Development Co. Ltd. Disulfiram doses and treatment regimen suitable for treatment of angiogenesis-dependent disorders
US9026372B2 (en) * 2007-11-21 2015-05-05 Accentia Biopharmaceuticals, Inc. Methods for providing a system of care for a high-dose oxazaphosphorine drug regimen
WO2009067699A2 (en) * 2007-11-21 2009-05-28 Accentia Biopharmaceuticals, Inc. Methods for providing a system of care for an oxazaphosphorine drug regimen
EP2632450A1 (en) * 2010-08-31 2013-09-04 Avidal Vascular GmbH Compositions comprising a taxane for coating medical devices
JP6206939B2 (ja) * 2011-10-11 2017-10-04 国立大学法人 千葉大学 肝がん幹細胞阻害剤
WO2014152207A1 (en) 2013-03-15 2014-09-25 Mylan Laboratories, Inc. Hot melt granulation formulations of poorly water-soluble active agents
WO2015120254A1 (en) * 2014-02-06 2015-08-13 Texas Tech University System Disulfiram compositions and treatments for brain tumors
GB201407806D0 (en) 2014-05-02 2014-06-18 Ucl Business Plc Treatment of fibrosis
GB201519643D0 (en) * 2015-11-06 2015-12-23 Univ Wolverhampton Disulfiram formulation
WO2017177947A1 (zh) 2016-04-13 2017-10-19 诺马（北京）科技有限公司 局部注射双硫仑制剂治疗胸腹膜癌症的方法
EP3311843A1 (en) 2016-10-13 2018-04-25 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Compositions comprising dithiocarbamate and cyclodextrin
US11298396B2 (en) 2017-03-17 2022-04-12 Osaka University Agent for inhibiting or reducing light sensitivity
EP3813805A4 (en) * 2018-06-27 2021-08-25 Children's Medical Center Corporation INFLAMMATION INHIBITION COMPOUNDS
US11311538B2 (en) 2018-07-13 2022-04-26 Yale University Compositions and methods for targeting cancers
EP3693740A1 (en) 2019-02-07 2020-08-12 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Improved dithiocarmabate based compounds, therapies and diagnostics
KR20210049403A (ko) * 2019-10-25 2021-05-06 연세대학교 산학협력단 암의 예방 또는 치료용 조성물
EP4135660A1 (en) * 2020-04-16 2023-02-22 Atossa Therapeutics, Inc. Compositions and methods to reduce the infectivity of a virus
WO2021231814A1 (en) * 2020-05-14 2021-11-18 The Trustees Of Columbia University In The City Of New York Compositions and methods for the treatment and prevention of vascular malformations
US12070468B2 (en) * 2020-05-14 2024-08-27 The Trustees Of Columbia University In The City Of New York Compositions and methods for the treatment and prevention of vascular malformations
WO2022061171A1 (en) * 2020-09-18 2022-03-24 Spring Discovery, Inc. Combination therapies with disulfiram
US11065214B1 (en) * 2020-09-18 2021-07-20 Spring Discovery, Inc. Combination therapies with disulfiram
CN114376997B (zh) * 2021-10-10 2023-04-28 深圳市人民医院 一种新型IRE1a抑制剂紫草素及与双硫仑协同抗肿瘤组合方式

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0284879A3 (en) * 1987-03-17 1990-10-17 Merrell Dow Pharmaceuticals Inc. Method of inhibiting interleukin-1 release
US4870101A (en) * 1987-03-17 1989-09-26 Merrell Dow Pharmaceuticals Inc. Method of inhibiting interleukin-1 release
US5807884A (en) 1992-10-30 1998-09-15 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases

Also Published As

Publication number Publication date
WO1999034784A2 (en) 1999-07-15
IL122892A0 (en) 1998-08-16
WO1999034784A3 (en) 2000-09-08
EP1047416B1 (en) 2008-07-23
EP1047416A2 (en) 2000-11-02
AU1888599A (en) 1999-07-26
ATE401879T1 (de) 2008-08-15
JP2002500180A (ja) 2002-01-08
DK1047416T3 (da) 2008-11-17
US6288110B1 (en) 2001-09-11

Similar Documents

Publication Publication Date Title
ATE401879T1 (de) Disulfiram enthaltende arzneimittel
IT8321039A0 (it) Composti eterociclici in cui l'eterosostituente e'ossigeno,zolfo,so,s o2 oppure nr2,utili nel trattamento delle neoplasie e dermatosi
ATE147618T1 (de) Kosmetisches und/oder dermatologisches mittel enthaltend thermal- oder mineralwasser und einen gegen akne oder älterung aktiven agentsien
FR2771004B1 (fr) Utilisation de derives de benzhydryl sulfinyle pour la fabrication de medicaments ayant un effet eveillant dans des situations de troubles de la vigilance d'origine medicamenteuse
EP0443007A4 (en) An external analgesic lotion and method of making
NO996314L (no) Fremgangsmåte for behandling av tobakk for å redusere innholdet av nitrosamin og produkter fremstilt av denne
DE69528604D1 (de) Medikamentenbehandlung erkrankter tiefliegender bereiche im inneren des körpers
ES2180646T3 (es) Formulaciones liquidas orales de alendronato.
MX9703694A (es) Tratamiento profilactico y terapeutico de la sensibilizacion e irritacion de la piel.
DE69426690D1 (de) Behandlung von atrophischer Haut und Vagina
ATE299022T1 (de) Verwendung von cyclopamine zur herstellung eines arzneimittels zur behandlung von psoriasis
IT8567279A1 (it) Apparecchio per l'applicazione controllata, sul tessuto umano, di sostanze riducenti per realizzare microabrasioni.
DE3683333D1 (de) Mittel zur behandlung von akne vulgaris und deren herstellung.
IT8620298A0 (it) Sali di diacetilreina e loro impiego terapeutico nel trattamento dell'artrosi.
IT1264530B (it) Impiego dei polisaccaridi nelle neuropatie atrofico degenerative
FR2755965B1 (fr) Composes biaromatiques, compositions pharmaceutiques et cosmetiques les contenant et utilisations
DE68913739D1 (de) Kosmetische und hautbehandlungs-zusammensetzungen.
KR890000097A (ko) 항레트로비루스 작용을 갖는 당단백질 처리 억제제
FR2713640B1 (fr) Nouveaux composés aromatiques polycycliques, compositions pharmaceutiques et cosmétiques les contenant et utilisations.
FI941345A7 (fi) Retinoidit ja niiden käyttö ihosairauksien ja leukemian hoitoon
ATE401855T1 (de) Stabile hautbehandlungsmittel enthaltend ein retinoid und ein retinoid-boostersystem
DE69326627D1 (de) Therapeutisches Mittel gegen drohenden Abortus
FI950725A7 (fi) Trisyklisen yhdisteen käyttö muistin ja tajunnan häiriöiden hoitoon tarkoitettujen lääkevalmisteiden valmistukseen
NO960545D0 (no) Behandling av skadelige virkninger i forbindelse med administrering av ekstracellulært hemoglobin
SE9002447D0 (sv) Foer hudlotioner, hudkraemer o.l. avsett koncentrat

Legal Events

Date Code Title Description
8364 No opposition during term of opposition